SPEECH-PROCESSING
4.2.2020 11:03:11 CET | Business Wire | Press release
Speech Processing Solutions , the market leader in professional dictation, has announced that its portfolio of speech-to-text software is now available on a subscription basis. Flexible low monthly subscription costs make it easier for organizations to take advantage of the full range of available speech-to-text services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005443/en/
Philips dictation and transcription software streamlines the document creation process and facilitates communication between authors and transcriptionists. It enables everything from automated file routing to an on-demand “pay as you go” transcription service or automatic speech recognition to help business of all sizes fulfill their unique needs.
“Philips speech-to-text software helps businesses reach their goals by helping them become even more efficient, profitable and successful, whether this means scoring new top clients or simply having more time for their current customers,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
High-tech innovation to boost voice-based productivity
Philips software is designed around the customers’ needs and has been developed in close collaboration with end-users. Philips understands that different businesses have personalized needs and preferences. Regardless of whether they are small, mid-sized or large, prefer an on-premise or cloud solution, or run an environment with a few laptops or a complex multi-branch setup across several countries, various voice-to-text options are available to help organizations address every business requirement.
The subscription-based speech-to-text portfolio includes Philips SpeechExec Pro, Philips SpeechExec Enterprise and SpeechLive. The new Philips SpeechExec Pro version 11.5 features a refreshed, more user-friendly interface and supports the latest operating systems available in the market. SpeechLive, Philips’s web dictation and transcription solution, now boasts a brand-new speech-to-text service that offers users speech recognition in real-time. This not only saves users time while working on documents, but also money and hassle as no additional speech recognition software needs to be purchased and installed. SpeechLive offers constant file access to increase mobility, helping professionals to work from anywhere and at any time. Now available as a one- or two-year subscription package, Philips SpeechExec Enterprise, which is ideal for large, multi-branch businesses, supports workflow processes that require central administration and virtual environments.
“Quick and effective communication is key in today’s complex business world. Working in a fast-paced environment requires effortless collaboration and efficient processes no matter what the size of your organization. Our Philips workflow software solutions allow you to do just that, while new subscription models enable businesses to be more agile and cost-efficient than ever before,” explains Dr. Brauner.
All Philips software is optimized to support the industry-leading range of Philips dictation devices including the SpeechMike series, the hands-free dictation headset SpeechOne and the Android-based SpeechAir.
For a free trial of Philips workflow solutions, go to: www.philips.com/speech
About Speech Processing Solutions
Speech Processing Solutions (SPS) is an international technology company and a global leader in dictation solutions. More than four million users worldwide work with speech-to-text solutions developed by SPS and sold under the Philips brand. These solutions include web-based and desktop workflow software as well as dictation devices. These smart solutions save users’ time and allow them to focus on their core tasks, making their business more efficient, customer-centric and profitable.
Headquartered in Vienna, Austria, SPS has regional offices in the United States, Canada, Australia, the United Kingdom, Germany, France, Belgium and Austria, as well as a network of more than 1000 distribution and implementation partners worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005443/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
